ES2811127T3 - Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial - Google Patents

Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial Download PDF

Info

Publication number
ES2811127T3
ES2811127T3 ES16182139T ES16182139T ES2811127T3 ES 2811127 T3 ES2811127 T3 ES 2811127T3 ES 16182139 T ES16182139 T ES 16182139T ES 16182139 T ES16182139 T ES 16182139T ES 2811127 T3 ES2811127 T3 ES 2811127T3
Authority
ES
Spain
Prior art keywords
ggf2
myelination
activation
erk
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16182139T
Other languages
English (en)
Spanish (es)
Inventor
Haesun Kim
Anthony O Caggiano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of ES2811127T3 publication Critical patent/ES2811127T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES16182139T 2008-02-29 2009-03-02 Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial Active ES2811127T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29

Publications (1)

Publication Number Publication Date
ES2811127T3 true ES2811127T3 (es) 2021-03-10

Family

ID=41016663

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16182139T Active ES2811127T3 (es) 2008-02-29 2009-03-02 Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial
ES09715322.5T Active ES2613177T3 (es) 2008-02-29 2009-03-02 Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09715322.5T Active ES2613177T3 (es) 2008-02-29 2009-03-02 Método para conseguir niveles plasmáticos deseados de factor de crecimiento glial 2

Country Status (11)

Country Link
US (5) US8410050B2 (https=)
EP (3) EP3120863B1 (https=)
JP (2) JP5697455B2 (https=)
CN (2) CN104645315A (https=)
AU (1) AU2009217606B2 (https=)
BR (1) BRPI0908271A2 (https=)
CA (1) CA2717193C (https=)
ES (2) ES2811127T3 (https=)
PL (2) PL3120863T3 (https=)
RU (3) RU2530650C2 (https=)
WO (1) WO2009108390A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108390A2 (en) 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP3777878A1 (en) 2008-08-15 2021-02-17 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
NZ625673A (en) 2009-10-14 2015-11-27 Acorda Therapeutics Inc Use of a neuregulin to treat peripheral nerve injury
US20130072437A1 (en) * 2010-05-28 2013-03-21 Mind-Nrg Sa Neuregulin isoforms,neuregulin polypeptides and uses thereof
EP2603221A4 (en) * 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION
EP3842059A1 (en) * 2012-03-30 2021-06-30 Acorda Therapeutics, Inc. Ggf2 to treat surgical peripheral nerve injury or neuropathic pain therefrom
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7319019B1 (en) * 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU3003701A (en) * 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
AU2004247025B8 (en) 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US20080213817A1 (en) * 2004-02-19 2008-09-04 Michael Karin Enhancement of Th2-Dependent and Inflammatory Response
EP1845985A4 (en) 2005-02-02 2011-10-12 Nexuspharma Inc AMIN DERIVATIVE COMPOSITIONS AND METHODS FOR TREATING VIRUS DISEASES RELATED TO CANCER Aetiology
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
WO2009108390A2 (en) 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
MX2012011473A (es) 2010-04-01 2012-11-16 Procter & Gamble Suavizante de telas.
EP2603221A4 (en) 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION

Also Published As

Publication number Publication date
AU2009217606B2 (en) 2015-03-05
BRPI0908271A2 (pt) 2017-06-13
EP2262527B1 (en) 2016-08-03
JP5697455B2 (ja) 2015-04-08
RU2019110452A (ru) 2020-10-09
RU2010139906A (ru) 2012-04-10
CA2717193C (en) 2022-08-16
US9744215B2 (en) 2017-08-29
US20160367634A1 (en) 2016-12-22
US20130345131A1 (en) 2013-12-26
CN102026651B (zh) 2015-06-03
RU2530650C2 (ru) 2014-10-10
WO2009108390A3 (en) 2010-11-18
RU2687097C2 (ru) 2019-05-07
JP5964920B2 (ja) 2016-08-03
US8410050B2 (en) 2013-04-02
US10675331B2 (en) 2020-06-09
US20180055909A1 (en) 2018-03-01
EP3120863B1 (en) 2020-05-06
EP2262527A2 (en) 2010-12-22
WO2009108390A2 (en) 2009-09-03
US9272015B2 (en) 2016-03-01
PL2262527T3 (pl) 2017-07-31
CN104645315A (zh) 2015-05-27
ES2613177T3 (es) 2017-05-23
PL2262527T4 (pl) 2017-07-31
RU2014131265A (ru) 2016-02-20
JP2011513310A (ja) 2011-04-28
CN102026651A (zh) 2011-04-20
US20100029559A1 (en) 2010-02-04
EP3750551A1 (en) 2020-12-16
AU2009217606A1 (en) 2009-09-03
CA2717193A1 (en) 2009-09-03
US20210060128A1 (en) 2021-03-04
PL3120863T3 (pl) 2021-02-22
EP3120863A1 (en) 2017-01-25
JP2015042656A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
ES2811127T3 (es) Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial
Jelkmann et al. Beneficial and ominous aspects of the pleiotropic action of erythropoietin
US11053321B2 (en) ErbB2 signaling and nerve regeneration
Syed et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine
Li et al. Angiotensin AT2 receptor protects against cerebral ischemia‐induced neuronal injury
Hata et al. RGMa inhibition promotes axonal growth and recovery after spinal cord injury
JP5905833B2 (ja) 心筋虚血−再潅流障害の予防、処置または遅延のための、ニューレグリンを含む組成物およびその利用
Xie et al. Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats
US20030113326A1 (en) Reducing myelin-mediated inhibition of axon regeneration
Yin et al. DLK silencing attenuated neuron apoptosis through JIP3/MA2K7/JNK pathway in early brain injury after SAH in rats
Joung et al. Secretion of EGF-like domain of heregulinβ promotes axonal growth and functional recovery of injured sciatic nerve
Deng et al. α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subunit composition and cAMP-response element-binding protein regulate oligodendrocyte excitotoxicity
AU2017203961B2 (en) Method for achieving desired glial growth factor 2 plasma levels
HK1152230B (en) Compositions for achieving desired glial growth factor 2 plasma levels